Philip T. Chase
Directeur Général chez Adimab LLC
Profil
Philip T.
Chase is currently the Chief Executive Officer at Adimab LLC since 2012.
Prior to his current position, he held various roles at different companies including Director at Invivyd, Inc., Chief Corporate Counsel at Transkaryotic Therapies, Inc., Vice President & General Counsel at EPIX Pharmaceuticals, Inc. and RenaMed Biologics, Inc., and Vice President-Legal Affairs at Alnylam Pharmaceuticals, Inc. Mr. Chase obtained a graduate degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from Colby College.
Postes actifs de Philip T. Chase
| Sociétés | Poste | Début |
|---|---|---|
Adimab LLC
 Adimab LLC BiotechnologyHealth Technology Adimab LLC provides human therapeutic antibodies. The firm has discovered antibodies for a wide variety of therapeutic targets within many disease areas, including oncology, immunomodulation, inflammation, neuroscience and pain, cardiovascular and metabolic disease and infectious disease. The company was founded in 2007 by Tillman Gerngross, Dane Wittrup and Errik Anderson and is headquartered in Lebanon, NH. | Directeur Général | 01/04/2022 |
Anciens postes connus de Philip T. Chase
| Sociétés | Poste | Fin |
|---|---|---|
| INVIVYD, INC. | Directeur/Membre du Conseil | - |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Conseiller Juridique Général | - |
| ALNYLAM PHARMACEUTICALS, INC. | Conseiller Juridique Général | - |
RenaMed Biologics, Inc.
 RenaMed Biologics, Inc. Medical/Nursing ServicesHealth Services RenaMed Biologics, Inc. provided clinical cellular therapy. The company was founded by H. David Humes, James P. Sherblom and Richard A. Andrews in 1995 and was headquartered in Lincoln, RI. | Conseiller Juridique Général | - |
EPIX Pharmaceuticals, Inc.
 EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA. | Conseiller Juridique Général | - |
Formation de Philip T. Chase
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| Colby College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| INVIVYD, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
EPIX Pharmaceuticals, Inc.
EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA. | Health Technology |
RenaMed Biologics, Inc.
RenaMed Biologics, Inc. Medical/Nursing ServicesHealth Services RenaMed Biologics, Inc. provided clinical cellular therapy. The company was founded by H. David Humes, James P. Sherblom and Richard A. Andrews in 1995 and was headquartered in Lincoln, RI. | Health Services |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Adimab LLC
Adimab LLC BiotechnologyHealth Technology Adimab LLC provides human therapeutic antibodies. The firm has discovered antibodies for a wide variety of therapeutic targets within many disease areas, including oncology, immunomodulation, inflammation, neuroscience and pain, cardiovascular and metabolic disease and infectious disease. The company was founded in 2007 by Tillman Gerngross, Dane Wittrup and Errik Anderson and is headquartered in Lebanon, NH. | Health Technology |
